The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
 
Anis Hamid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; MSD
Travel, Accommodations, Expenses - UroToday
 
Santosh Gupta
Employment - Epic Sciences
 
Shivakumar Keerthikumar
No Relationships to Disclose
 
Anupama Pasam
No Relationships to Disclose
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Ernest Lam
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Rick Wenstrup
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Travel, Accommodations, Expenses - Epic Sciences
 
Louise Emmett
Consulting or Advisory Role - Clarity Pharmaceuticals; Noxopharm
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
David L. Goode
No Relationships to Disclose
 
Michael S Hofman
Consulting or Advisory Role - Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Bayer (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen; Novartis
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Genentech (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)